Gregoriadis G
Centre for Drug Delivery Research, School of Pharmacy, University of London, UK.
J Drug Target. 1994;2(5):351-6. doi: 10.3109/10611869408996809.
Animal immunization studies by numerous laboratories have shown that liposomes promote humoural and cell-mediated immunity to a wide spectrum of bacterial, protozoan and viral antigens as well as tumour cell antigens, venoms and allergens. Adjuvanticity depends on liposomal structural characteristics which determine vesicle fate in vivo and, thus, the mode of antigen interaction with antigen-presenting cells. Adjuvanticity is further promoted by receptor mediated targeting of liposomes to macrophages, or the presence of other adjuvants including cytokines. The immunoadjuvant function of liposomes is supplemented by their ability to act as a carrier for co-entrapped B and T-cell epitopes, thus eliminating the need for a carrier protein. Recently, a technique has been developed for the entrapment of live or attenuated microbial vaccines into giant liposomes under conditions which retain their viability. Liposomes containing microbial vaccines (together with other soluble antigens or cytokines) could be used as carriers of vaccines in cases where there is a need to prevent interaction of vaccines with maternal antibodies or preformed antibodies to vaccine impurities.
众多实验室进行的动物免疫研究表明,脂质体可促进针对多种细菌、原生动物和病毒抗原以及肿瘤细胞抗原、毒液和过敏原的体液免疫和细胞介导免疫。佐剂活性取决于脂质体的结构特征,这些特征决定了体内囊泡的命运,进而决定了抗原与抗原呈递细胞相互作用的方式。通过受体介导的脂质体靶向巨噬细胞或存在包括细胞因子在内的其他佐剂,可进一步增强佐剂活性。脂质体的免疫佐剂功能还体现在它们能够作为共包封的B细胞和T细胞表位的载体,从而无需载体蛋白。最近,已开发出一种技术,可在保持其活力的条件下将活的或减毒的微生物疫苗包封到巨型脂质体中。在需要防止疫苗与母体抗体或针对疫苗杂质的预先形成的抗体相互作用的情况下,含有微生物疫苗(以及其他可溶性抗原或细胞因子)的脂质体可用作疫苗载体。